V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20216244 | 20168591 | 1.63 | null | null | 2017-03-15 | 2017-03-26 | null | 02 | N | CISPLATIN + FLUOROURACIL | 101755791 |
| 20216252 | 20168594 | 1.75 | 82 | null | null | 2020-01-21 | null | 02 | null | CARBOPLATIN + ETOPOSIDE | 101051557 |
| 20216254 | 20168595 | 1.6 | 74.4 | null | 2022-01-21 | 2022-01-29 | NIVOLUMAB | 02 | null | NIVOLUMAB | 101682879 |
| 20216256 | 20168596 | 1.63 | null | null | 2019-11-13 | 2019-12-11 | CISPLATIN + FLUOROURACIL | N | null | CISPLATIN + FLUOROURACIL | 101864854 |
| 20216261 | 20168597 | 1.77 | 71 | 03 | null | 2017-02-17 | null | 02 | N | CISPLATIN + FLUOROURACIL | 101864460 |
| 20216267 | 20168598 | null | null | Palliative (P) | 2020-04-15 | 2020-04-28 | NIVOLUMAB | 02 | N | NIVOLUMAB | 101024602 |
| 20216275 | 20168599 | 1.55 | 50 | null | 2017-04-14 | 2017-05-11 | NIVOLUMAB | 02 | N | NIVOLUMAB | 101865503 |
| 20216277 | 20168600 | 1.62 | 78.4 | Palliative (P) | 2016-06-16 | 2016-07-02 | null | 02 | N | ECX | 101139226 |
| 20216283 | 20168602 | 1.63 | null | null | 2018-02-14 | 2018-02-17 | ECX | 2 | null | ECX | 100093604 |
| 20216300 | 20168603 | 1.72 | 94.7 | null | 2022-01-16 | 2022-01-16 | CARBOPLATIN + ETOPOSIDE | 02 | N | CARBOPLATIN + ETOPOSIDE | 100250445 |
| 20216305 | 20168604 | 1.55 | 75.6 | null | 2019-07-27 | 2019-08-06 | null | 2 | null | NIVOLUMAB | 100185847 |
| 20216308 | 20168605 | null | 79.1 | Palliative (P) | 2021-12-25 | 2022-01-08 | NIVOLUMAB | 02 | N | NIVOLUMAB | 101827284 |
| 20216313 | 20168606 | 1.78 | null | Curative (C) | 2021-12-15 | 2021-12-29 | Panitumumab | 02 | N | PANITUMUMAB | 100925366 |
| 20216314 | 20168607 | 1.7 | 82 | null | 2018-11-10 | 2018-11-25 | null | 02 | null | ECX | 100441786 |
| 20216326 | 20168608 | null | 88 | Curative (C) | 2018-09-12 | 2018-09-18 | ECX | N | N | ECX | 100039239 |
| 20216338 | 20168609 | 1.65 | 56.4 | null | 2022-03-10 | 2022-03-20 | null | N | null | ECX | 100013830 |
| 20216344 | 20168610 | 1.76 | null | Palliative (P) | 2020-07-07 | 2020-07-25 | Panitumumab | null | N | PANITUMUMAB | 100975099 |
| 20216345 | 20168611 | 1.78 | 94.7 | null | 2017-04-16 | 2017-05-14 | Cisplatin +Fluorouracil (3 wk) | 02 | N | CISPLATIN + FLUOROURACIL | 101473051 |
| 20216348 | 20168612 | 1.63 | 52.8 | Palliative (P) | 2018-02-25 | 2018-04-06 | Cisplatin + Fluorouracil + RT 5day | 02 | N | CISPLATIN + FLUOROURACIL | 100894221 |
| 20216355 | 20168613 | 1.64 | 63.7 | null | 2016-09-29 | 2016-11-02 | null | 02 | N | CISPLATIN + FLUOROURACIL | 101220769 |
| 20216359 | 20168614 | 1.85 | 78.2 | Palliative (P) | 2019-02-06 | 2019-02-09 | null | 02 | N | CISPLATIN + FLUOROURACIL | 101786222 |
| 20216378 | 20168617 | 1.73 | null | Neo-adjuvant (N) | null | 2020-04-06 | null | 2 | N | ECX | 101308670 |
| 20216395 | 20168618 | 1.7 | 52.7 | Palliative (P) | 2019-03-13 | 2019-05-10 | NIVOLUMAB | 02 | N | NIVOLUMAB | 101416159 |
| 20216398 | 20168619 | 1.62 | null | Neo-adjuvant (N) | null | 2019-10-22 | null | 02 | N | PANITUMUMAB | 100901447 |
| 20216401 | 20168620 | 1.67 | 89.8 | null | 2021-07-15 | 2021-07-15 | NIVOLUMAB | 02 | N | NIVOLUMAB | 100335388 |
| 20216410 | 20168621 | 1.72 | 52.5 | Curative (C) | 2020-03-21 | 2020-04-15 | null | 02 | N | CARBOPLATIN + ETOPOSIDE | 101170759 |
| 20216417 | 20168622 | 1.59 | 81.3 | Palliative (P) | 2015-08-26 | 2016-07-15 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100464567 |
| 20216421 | 20168623 | 1.79 | 114.2 | null | 2018-12-13 | 2018-12-14 | EOX | 2 | null | OXALIPLATIN + RALTITREXED | 101309431 |
| 20216422 | 20168624 | 1.94 | 60.8 | Adjuvant (A) | 2019-08-19 | 2019-09-14 | Cetuximab + FLUOROURACIL + FOLINIC ACID + IRINOTECAN | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 100349528 |
| 20216424 | 20168625 | 1.64 | 93 | null | 2017-02-18 | 2017-02-19 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 02 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101711579 |
| 20216428 | 20168626 | 1.83 | 46.9 | null | 2019-08-05 | 2019-08-14 | Cetuximab + FOLFIRI cycle 2 onwards | null | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101114877 |
| 20216432 | 20168627 | 1.83 | 102 | Adjuvant (A) | null | 2021-07-23 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 2 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101148368 |
| 20216438 | 20168628 | 1.59 | 57.1 | Palliative (P) | 2017-09-09 | 2017-09-13 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | CETUXIMAB + IRINOTECAN + MDG | 100418981 |
| 20216441 | 20168629 | 1.6 | 89.9 | Palliative (P) | 2019-10-07 | 2019-10-15 | EOX | N | N | CETUXIMAB + IRINOTECAN + MDG | 101643539 |
| 20216442 | 20168630 | 1.73 | 93 | Palliative (P) | 2019-10-26 | 2019-10-26 | EOX | N | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101830442 |
| 20216443 | 20168631 | 1.75 | 73.3 | Palliative (P) | null | 2020-02-06 | Cetuximab + FOLFIRI cycle 2 onwards | Y | N | CETUXIMAB + IRINOTECAN + MDG | 101628047 |
| 20216449 | 20168632 | 1.56 | 105 | null | 2020-01-07 | 2020-02-09 | EOX | 1 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100648413 |
| 20216461 | 20168633 | 1.75 | 65 | Neo-adjuvant (N) | 2018-06-21 | 2018-07-05 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 02 | Y | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101038626 |
| 20216463 | 20168634 | 1.78 | 154 | Palliative (P) | 2018-12-24 | 2019-01-09 | Trial Unspecified | 02 | N | TRIAL | 101021875 |
| 20216469 | 20168635 | 1.81 | 73.3 | Palliative (P) | 2017-10-05 | 2017-10-05 | Sorafenib | N | N | SORAFENIB | 100823395 |
| 20216473 | 20168636 | 1.7 | 93.1 | Palliative (P) | 2020-08-21 | 2020-08-21 | EOX | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101299499 |
| 20216479 | 20168637 | 1.71 | 60 | Palliative (P) | 2018-10-10 | 2018-10-21 | EOX | 02 | N | EOX | 101388287 |
| 20216482 | 20168638 | 1.72 | 0 | null | 2018-04-27 | 2018-05-20 | EOX | 99 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100608251 |
| 20216513 | 20168639 | 1.67 | 102 | Palliative (P) | 2018-03-21 | 2018-10-01 | EOX | N | N | EOX | 100200803 |
| 20216517 | 20168640 | 1.79 | 93 | null | 2016-05-03 | 2016-05-25 | Cetuximab + Oxaliplatin + MdG Maint | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100323363 |
| 20216519 | 20168642 | 1.8 | 66.4 | Palliative (P) | null | 2017-03-23 | EOX | N | N | EOX | 101335262 |
| 20216522 | 20168643 | 1.65 | 69.3 | Palliative (P) | 2018-05-16 | 2018-05-16 | Sorafenib | 02 | N | SORAFENIB | 100486502 |
| 20216525 | 20168644 | 1.81 | 81.2 | Palliative (P) | 2018-09-26 | 2018-09-27 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 100314285 |
| 20216528 | 20168645 | 1.87 | 114 | 03 | 2020-11-03 | 2020-11-24 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 100472166 |
| 20216538 | 20168646 | 1.59 | 61.7 | Neo-adjuvant (N) | 2017-01-05 | 2017-01-08 | Capecitabine 35days + RT | 99 | Y | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100368325 |